dc.creatorDOI, Masanori
dc.creatorTANABE, Kazuyuki
dc.creatorTACHIBANA, Shin-Lchiro
dc.creatorHAMAI, Meiko
dc.creatorTACHIBANA, Mayumi
dc.creatorMITA, Toshihiro
dc.creatorYAGI, Masanori
dc.creatorZEYREK, Fadile Yildiz
dc.creatorFERREIRA, Marcelo U.
dc.creatorOHMAE, Hiroshi
dc.creatorKANEKO, Akira
dc.creatorRANDRIANARIVELOJOSIA, Milijaona
dc.creatorSATTABONGKOT, Jetsumon
dc.creatorCAO, Ya-Ming
dc.creatorHORII, Toshihiro
dc.creatorTORII, Motomi
dc.creatorTSUBOI, Takafumi
dc.date.accessioned2012-10-20T03:26:37Z
dc.date.accessioned2018-07-04T15:36:52Z
dc.date.available2012-10-20T03:26:37Z
dc.date.available2018-07-04T15:36:52Z
dc.date.created2012-10-20T03:26:37Z
dc.date.issued2011
dc.identifierVACCINE, v.29, n.26, p.4308-4315, 2011
dc.identifier0264-410X
dc.identifierhttp://producao.usp.br/handle/BDPI/28524
dc.identifier10.1016/j.vaccine.2011.04.028
dc.identifierhttp://dx.doi.org/10.1016/j.vaccine.2011.04.028
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1625167
dc.description.abstractPfs230, surface protein of gametocyte/gamete of the human malaria parasite, Plasmodium falciparum, is a prime candidate of malaria transmission-blocking vaccine. Plasmodium vivax has an ortholog of Pfs230 (Pvs230), however, there has been no study in any aspects on Pvs230 to date. To investigate whether Pvs230 can be a vivax malaria transmission-blocking vaccine, we performed evolutionary and population genetic analysis of the Pvs230 gene (pvs230: PVX_003905). Our analysis of Pvs230 and its orthologs in eight Plasmodium species revealed two distinctive parts: an interspecies variable part (IVP) containing species-specific oligopeptide repeats at the N-terminus and a 7.5 kb interspecies conserved part (ICP) containing 14 cysteine-rich domains. Pvs230 was closely related to its orthologs, Pks230 and Pcys230, in monkey malaria parasites. Analysis of 113 pvs230 sequences obtained from worldwide, showed that nucleotide diversity is remarkably low in the non-repeat 8-kb region of pvs230 (theta pi = 0.00118) with 77 polymorphic nucleotide sites, 40 of which results in amino acid replacements. A signature of purifying selection but not of balancing selection was seen on pvs230. Functional and/or structural constraints may limit the level of polymorphism in pvs230. The observed limited polymorphism in pvs230 should ground for utilization of Pvs230 as an effective transmission-blocking vaccine. (C) 2011 Elsevier Ltd. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCI LTD
dc.relationVaccine
dc.rightsCopyright ELSEVIER SCI LTD
dc.rightsrestrictedAccess
dc.subjectMalaria
dc.subjectPlasmodium vivax
dc.subjectPvs230
dc.subjectGametocyte surface antigen
dc.subjectPurifying selection
dc.subjectTransmission-blocking vaccine
dc.titleWorldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución